Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A HIV-2-based self-inactivating vector for enhanced gene transduction.

Sayandip Mukherjee1, Hui-Ling Rose Lee, Annmarie L Pacchia

  • 1Department of Molecular Genetics, Microbiology and Immunology, Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854, USA.

Journal of Biotechnology
|September 19, 2006
PubMed
Summary

This study introduces safer HIV-2 based vectors for gene therapy, achieving high titers and long-term expression in various cells. These vectors offer enhanced safety by reducing recombination potential for clinical applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GS143, an inhibitor of E3 ligase β-TrCP, reverses HIV-1 latency without activating T cells via unconventional activation of NFκB.

PLoS pathogens·2025
Same author

Chemical inactivation of two non-enveloped viruses results in distinct thermal unfolding patterns and morphological alterations.

BMC microbiology·2024
Same author

Valproic Acid Confers Functional Pluripotency to Human Amniotic Fluid Stem Cells in a Transgene-free Approach.

Molecular therapy : the journal of the American Society of Gene Therapy·2024
Same author

Development of a pseudo-typed virus particle based method to determine the efficacy of virucidal agents.

Scientific reports·2024
Same author

Personal care formulations demonstrate virucidal efficacy against multiple SARS-CoV-2 variants of concern: Implications for hand hygiene and public health.

PLOS global public health·2023
Same author

CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva.

Journal of medical microbiology·2022

Area of Science:

  • Gene Therapy
  • Viral Vector Development
  • Molecular Virology

Background:

  • Human Immunodeficiency Virus type 1 (HIV-1) based vectors face safety concerns in clinical trials due to the virus's pathogenicity.
  • Human Immunodeficiency Virus type 2 (HIV-2) presents a less pathogenic alternative for developing safer gene delivery systems.

Purpose of the Study:

  • To develop and characterize novel HIV-2 based self-inactivating lentiviral vectors for gene therapy applications.
  • To assess the efficiency, targeting capabilities, and safety profile of these HIV-2 vectors.

Main Methods:

  • Construction of HIV-2 based self-inactivating vectors with significant deletion in the U3 region.
  • Evaluation of vector production titers using exogenous promoters for viral RNA expression.
  • Assessment of vector transduction efficiency in diverse mammalian cell types, including primary neuronal cells.

Related Experiment Videos

  • Analysis of long-term gene expression and cross-packaging into HIV-1 cores.

    • Main Results:

    • High vector titers were achieved when using an exogenous promoter to drive viral RNA expression.
    • The HIV-2 vectors demonstrated broad tropism, effectively targeting various mammalian cells, including primary neurons.
    • Sustained, long-term gene expression was observed from the engineered vectors.
    • Effective cross-packaging of HIV-2 vectors into HIV-1 cores was demonstrated, potentially enhancing system safety.

    Conclusions:

    • HIV-2 based vectors are a promising safer alternative to HIV-1 based vectors for gene therapy.
    • The developed vectors exhibit efficient transduction, broad targeting, and sustained expression, suitable for therapeutic applications.
    • Cross-packaging into HIV-1 cores offers an additional safety feature by minimizing recombination risks.